首页> 外文期刊>Advances in Pharmacology and Pharmacy >Effect of Quercetin Supplement on Some Bone Mineralization Biomarkers in Diabetic Type 2 Patients
【24h】

Effect of Quercetin Supplement on Some Bone Mineralization Biomarkers in Diabetic Type 2 Patients

机译:槲皮素对2型糖尿病患者某些骨矿化生物标志物的影响

获取原文
       

摘要

Background: Diabetes associated with multiple metabolic problems in the body, including bone mineralization remodeling, osteoporosis and increase risk of fracture. Quercetin is natural flavonoids and according to animal studies; it has potent antioxidant, antidiabetic and protective effect against bone loss due to various causes. Objectives: explore effect of quercetin as nutritional supplement administrated orally on some bone mineralization bio-markers such as calcium, vitamin D and osteocalcin in Iraqi diabetic patients. Methods: interventional double-blind placebo randomized controlled study in which 40 patients with type 2 diabetes mellitus (age range 40-45) assigned randomly (using simple randomization) in either control (n=20) or study (n=20) group. Study group received Quercetin oral supplement as 500mg capsule once daily for three months. Venous blood was used for measuring Serum calcium, 25(OH) vitamin D and osteocalcin at base line and after 3 months. Results: After 3 months treatment with Quercetin; levels of Osteocalcin (28.1±7.6), serum calcium (9.2±1.8) and 25(OH) vitamin D (26.6±8.7) were significantly (p<0.05) higher than pretreatment values of osteocalcin (24.0±8.6); serum calcium (7.0±2.2) and 25(OH) vitamin D (20.6±7.7) and control values of serum calcium (6.8±2.0) and 25(OH) vitamin D (20.8±7.4), but not Osteocalcin (25.2±9.0). There was also significant correlation between use of quercetin; elevation of serum calcium and osteocalcin (r= 0.454; p= 0.032), indicating modulation in bone mineralization. Conclusions: Quercetin's use in diabetic patients may elevate Serum level of Calcium; 25(OH) vitamin D and may modulate bone mineralization represented by elevation of osteocalcin.
机译:背景:与体内多种代谢问题相关的糖尿病,包括骨矿化重塑,骨质疏松和增加骨折风险。槲皮素是天然类黄酮,根据动物研究;它具有有效的抗氧化剂,抗糖尿病和防止因各种原因引起的骨质流失的保护作用。目的:探讨槲皮素作为口服营养品对伊拉克糖尿病患者某些骨矿化生物标志物(如钙,维生素D和骨钙蛋白)的作用。方法:介入性双盲安慰剂随机对照研究,其中40例2型糖尿病患者(年龄范围40-45)随机(采用简单随机分组)分配为对照组(n = 20)或研究(n = 20)组。研究组每天服用一次槲皮素口服补充剂500毫克胶囊,持续三个月。在基线和3个月后,静脉血用于测量血清钙,25(OH)维生素D和骨钙素。结果:用槲皮素治疗3个月后;骨钙蛋白(28.1±7.6),血清钙(9.2±1.8)和25(OH)维生素D(26.6±8.7)的水平显着(p <0.05)高于骨钙素的预处理值(24.0±8.6);血清钙(7.0±2.2)和25(OH)维生素D(20.6±7.7)以及血清钙(6.8±2.0)和25(OH)维生素D(20.8±7.4)的对照值,而不是骨钙蛋白(25.2±9.0) )。槲皮素的使用之间也有显着的相关性。血清钙和骨钙素升高(r = 0.454; p = 0.032),表明骨矿化的调节。结论:槲皮素在糖尿病患者中的使用可能会升高血清钙水平。 25(OH)维生素D,并可能调节骨钙素升高所代表的骨矿化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号